Earnings History Data for Sangamo Therapeutics, Inc. (SGMO) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
12-11-2024	AH		SGMO	Sangamo Therapeutics, Inc.	597.59	0.04	-0.07	-0.34	Sangamo Therapeutics GAAP EPS of $0.04 beats by $0.08, revenue of $49.41M beats by $24.34M [11/12/2024 4:03 PM]	2.45	-0.26 (-9.59%)	2.28	-0.43 (-15.87%)	0.29 - 3.18	8,416,685	10,770,000	642,617
Sangamo Therapeutics GAAP EPS of $0.04 beats by $0.08, revenue of $49.41M beats by $24.34M [11/12/2024 4:03 PM] Sangamo Therapeutics Q3 beats propel stock 5% higher [11/12/2024 5:08 PM] Sangamo Therapeutics files for mixed shelf offering [11/12/2024 5:57 PM] Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results [2024-11-12 04:01PM]
06-08-2024	AH		SGMO	Sangamo Therapeutics, Inc.	146.25	-0.17	-0.16	-0.37	Sangamo Therapeutics GAAP EPS of -$0.18 misses by $0.03, revenue of $0.3M misses by $7.96M [8/6/2024 4:38 PM]	0.8558	-0.13 (-13.57%)	0.98	-0.01 (-1.44%)	0.29 - 1.48	18,935,360	67,320,000	2,551,508
Roche, Sangamo ink licensing deal for neuro drugs [8/6/2024 9:03 AM] Sangamo Therapeutics GAAP EPS of -$0.18 misses by $0.03, revenue of $0.3M misses by $7.96M [8/6/2024 4:38 PM]
09-05-2024	AH		SGMO	Sangamo Therapeutics, Inc.	96.59	-0.27	-0.22	0.12	Sangamo Therapeutics GAAP EPS of -$0.27 misses by $0.05, revenue of $0.48M misses by $5.88M [5/9/2024 4:10 PM]	0.5512	0.03 (5.31%)	0.53	0.01 (1.13%)	0.29 - 1.67	4,600,658	1,220,000	75,357
Sangamo Therapeutics GAAP EPS of -$0.27 misses by $0.05, revenue of $0.48M misses by $5.88M [5/9/2024 4:10 PM]
01-11-2023	AH		SGMO	Sangamo Therapeutics, Inc.	93.30	-0.34	-0.33	-0.34	Sangamo Therapeutics GAAP EPS of -$0.59 misses by $0.26, revenue of $9.39M misses by $1.01M [11/1/2023 4:04 PM]	0.46	-0.13 (-22.14%)	0.59	0.0 (-0.12%)	0.44 - 4.49	2,592,332	1,360,000	14,387
Sangamo Therapeutics GAAP EPS of -$0.59 misses by $0.26, revenue of $9.39M misses by $1.01M [11/1/2023 4:04 PM]
08-08-2023	AH		SGMO	Sangamo Therapeutics, Inc.	202.75	-0.37	-0.35	-0.29	Sangamo Therapeutics GAAP EPS of -$0.66 misses by $0.32, revenue of $6.84M misses by $8.49M [8/8/2023 4:15 PM]	1.05	-0.08 (-7.46%)	1.12	-0.02 (-1.75%)	1.04 - 6.42	1,961,321	1,110,000	3,624
Sangamo Therapeutics GAAP EPS of -$0.66 misses by $0.32, revenue of $6.84M misses by $8.49M [8/8/2023 4:15 PM]
22-02-2023	AH	4:00 PM ET (Feb 22)	SGMO	Sangamo Therapeutics, Inc.	503.11	-0.32	-0.36	-0.26	Sangamo Therapeutics GAAP EPS of -$0.32 beats by $0.04, revenue of $27.23M beats by $0.37M [2/22/2023 5:28 PM]	2.91	0.0 (0.00%)	3.15	0.24 (8.25%)	2.72 - 6.42	1,126,295	1,230,000	28,881
Sangamo Therapeutics GAAP EPS of -$0.32 beats by $0.04, revenue of $27.23M beats by $0.37M [2/22/2023 5:28 PM] Sangamo Therapeutics Q4 2022 Earnings Preview [2/22/2023 5:35 PM]
03-11-2022	AH	4:00 PM ET (Nov 3)	SGMO	Sangamo Therapeutics, Inc.	687.27	-0.34	-0.35	-0.33	Sangamo Therapeutics GAAP EPS of -$0.34 beats by $0.02, revenue of $26.5M misses by $0.29M [11/3/2022 4:02 PM]	3.59	-0.56 (-13.49%)	4.24	0.09 (2.17%)	3.12 - 11.49	1,409,614	1,100,000	143
Sangamo Therapeutics GAAP EPS of -$0.34 beats by $0.02, revenue of $26.5M misses by $0.29M [11/3/2022 4:02 PM]
04-08-2022	AH	4:00 PM ET (Aug 4)	SGMO	Sangamo Therapeutics, Inc.	660.09	-0.29	-0.35	-0.33	Sangamo Therapeutics GAAP EPS of -$0.29 beats by $0.06, revenue of $29.38M beats by $4.75M [8/4/2022 4:03 PM]	5.20	0.43 (9.01%)	5.20	0.0 (0.00%)	3.12 - 11.49	1,386,218	1,340,000	7,817
Sangamo Therapeutics GAAP EPS of -$0.29 beats by $0.06, revenue of $29.38M beats by $4.75M [8/4/2022 4:03 PM] Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results [Aug-04-22 04:01PM]
05-05-2022	AH	4:00 PM ET (May 5)	SGMO	Sangamo Therapeutics, Inc.	651.19	-0.30	-0.32	-0.32	Sangamo Therapeutics GAAP EPS of -$0.30 beats by $0.01, revenue of $28.23M beats by $0.94M [5/5/2022 4:06 PM]	4.14	-0.16 (-3.72%)	4.14	0.0 (0.00%)	3.87 - 12.83	1,424,526	1,270,000	42,818
Sangamo Therapeutics GAAP EPS of -$0.30 beats by $0.01, revenue of $28.23M beats by $0.94M [5/5/2022 4:06 PM] Sangamo Therapeutics stock slips despite Q1 revenue beat [5/6/2022 11:02 AM] Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates [May-04-22 06:35PM] Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results [May-05-22 04:01PM] Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates [May-05-22 05:45PM]
24-02-2022	AH	4:00 PM ET (Feb 24)	SGMO	Sangamo Therapeutics, Inc.	836.17	-0.26	-0.34	-0.29	Sangamo Therapeutics GAAP EPS of -$0.26 beats by $0.09, revenue of $28M beats by $0.64M [2/24/2022 4:02 PM]	5.79	0.08 (1.40%)	5.71	0.0 (0.00%)	5.13 - 13.93	434,484	1,360,000	275,228
Sangamo Therapeutics GAAP EPS of -$0.26 beats by $0.09, revenue of $28M beats by $0.64M [2/24/2022 4:02 PM] Sangamo Therapeutics rises 5% after hours following Q4 earnings [2/24/2022 6:03 PM] Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights [Feb-24-22 04:01PM] Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates [Feb-24-22 06:20PM]
04-11-2021	PM	7:00 AM ET (Nov 4)	SGMO	Sangamo Therapeutics, Inc.	1,260	-0.33	-0.34	-0.01	Sangamo Therapeutics EPS beats by $0.01, beats on revenue [11/4/2021 9:10 AM]	10.89	1.75 (19.15%)	10.89	0.0 (0.00%)	7.89 - 19.43	6,536,476	1,290,000	17,394
Sangamo Therapeutics Q3 2021 Earnings Preview [11/3/2021 11:08 AM] Sangamo Therapeutics EPS beats by $0.01, beats on revenue [11/4/2021 9:10 AM] Preliminary phase 1/2 data supports Sangamo Fabry disease gene therapy candidate [11/4/2021 10:31 AM] Sangamo up 21% following Q3 earnings beat, phase 1 Fabry candidate update [11/4/2021 11:42 AM] Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated -Gal A Enzyme Activity in Patients With Fabry Disease [Nov-04-21 08:00AM] Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results [Nov-04-21 09:05AM] Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates [Nov-04-21 10:25AM] Why Did Sangamo Stock Jump 20% Today? [Nov-04-21 05:20PM]
05-08-2021	AH	4:00 PM ET (Aug 5)	SGMO	Sangamo Therapeutics, Inc.	1,380	-0.33	-0.30	-0.26	Sangamo Therapeutics EPS misses by $0.02, beats on revenue; reaffirms full year guidance [8/5/2021 4:04 PM]	9.76	-0.21 (-2.11%)	9.64	-0.33 (-3.31%)	9.05 - 19.43	1,022,384	660,000	185,575
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results [Aug-05-21 04:01PM] Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates [Aug-05-21 05:45PM]
04-05-2021	AH	4:00 PM ET (May 4)	SGMO	Sangamo Therapeutics, Inc.	1,710	-0.32	-0.29	-0.37	Sangamo Therapeutics EPS misses by $0.02, beats on revenue [5/4/2021 4:05 PM]	10.39	-0.97 (-8.54%)	10.39	0.0 (0.00%)	8.27 - 19.43	1,491,049	900,000	8,626
Intellia and Sangamo preferred as RBC extends gene editing coverage [5/4/2021 1:57 PM] Sangamo Therapeutics EPS misses by $0.02, beats on revenue [5/4/2021 4:05 PM] Sangamo shares fall after hours as Q1 net loss widens, misses on EPS [5/4/2021 5:39 PM] Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences [May-03-21 04:30PM] Sangamo Therapeutics, Inc. to Host Earnings Call [May-04-21 03:15PM] Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results [May-04-21 04:01PM] Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates [May-04-21 05:25PM] Sangamo Therapeutics Inc (SGMO) Q1 2021 Earnings Call Transcript [May-05-21 05:01AM]
24-02-2021	AH	4:00 PM ET (Feb 24)	SGMO	Sangamo Therapeutics, Inc.	1,780	-0.29	-0.18	0.04	Sangamo Therapeutics EPS misses by $0.08, misses on revenue [2/24/2021 4:01 PM]	11.20	-1.32 (-10.50%)	12.12	-0.40 (-3.19%)	4.81 - 19.43	2,001,348	1,326,930	2,500
Sangamo Therapeutics EPS misses by $0.08, misses on revenue [2/24/2021 4:01 PM] Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results [Feb-24-21 04:01PM]
04-11-2020	AH	4:00 PM ET (Nov 4)	SGMO	Sangamo Therapeutics, Inc.	1,460	-0.01	-0.24	-0.24	Sangamo Therapeutics EPS beats by $0.24, beats on revenue [11/4/2020 4:06 PM]	11.99	0.17 (1.44%)	11.99	0.0 (0.00%)	4.81 - 13.20	2,004,513	1,469,180	20,945

05-08-2020	AH	4:00 PM ET (Aug 5)	SGMO	Sangamo Therapeutics, Inc.	1,530	-0.26	0.41	-0.26	Sangamo Therapeutics EPS misses by $0.37, misses on revenue [8/5/2020 4:06 PM]	12.32	0.82 (7.13%)	11.38	-0.12 (-1.04%)	4.81 - 12.91	2,678,723	1,825,870	71,950